- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01690312
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study involves fasted and post-prandial components.
Fasted Study:
Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.
There will be a 4-week washout period during the two Treatment Periods.
Post-prandial study:
Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Guelph, Ontario, Kanada, N1G 0B4
- Nutrasource Diagnostics Inc.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Be an adult between the ages of 18 and 70;
- Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
- Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
- Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
- Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
- Have a Body Mass Index (BMI) less than 35.0
- Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.
Exclusion Criteria:
- Be younger than 18 years of age or older than 70 years of age;
- Be an adult pre- or peri-menopausal female;
- Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
- Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
- Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
- Have high blood pressure [greater than 140/100]
- Have a Body Mass Index (BMI) equal to or greater than 35.0
- Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
- Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
- Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
- Consume more than two (2) fish meals on a weekly basis
- Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
- Anticipate or have planned surgery during the course of the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 1 (Dietary Supplement - Fish Oil)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
|
|
Experimental: 2 (Placebo)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Triglyceride [TG]
Zeitfenster: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
|
0 and 4 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Glucose
Zeitfenster: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Insulin
Zeitfenster: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Total cholesterol [TC]
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-density lipoprotein [HDL]
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Low-density lipoprotein [LDL]
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Very low-density lipoprotein [VLDL]
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Lipoprotein A
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Intermediate-density lipoprotein [IDL]
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Remnant Lipoproteins
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-sensitivity C-Reactive Protein [hs-CRP]
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Homocysteine
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Essential Fatty Acid Profile
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein B
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein A-1
Zeitfenster: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Alison Duncan, Ph.D., R.D., University of Guelph
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Insulin
- Menschen
- Herzkreislauferkrankung
- DHA
- Fischöl
- Statine
- Glucose
- Triglyceride
- Postprandial
- Homocystein
- EPA
- Lipoproteine
- Fasten
- Apolipoprotein B
- High-DHA
- Total cholesterol [TC]
- High-density lipoprotein [HDL2, HDL3]
- Low-density lipoprotein [LDL1+2+3+4]
- Lipoprotein A [Lp(a)]
- Intermediate-density lipoprotein (IDL)
- Very low-density lipoprotein (VLDL1+2, VLDL3)
- Remnant Lipoproteins
- High-sensitivity C-Reactive Protein [hs-CRP]
- Essential Fatty Acid Profile
- Apolipoprotein A-1
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 11-09-002
- 150038 (Health Canada)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fish Oil
-
Hospital Infantil de Mexico Federico GomezCentro Universitario del Sur, Guadalajara; Instituto de Servicios Descentralizados...AbgeschlossenInsulinresistenz | Fettleibigkeit bei Kindern | StoffwechselkomplikationMexiko
-
Pontificia Universidad Catolica de ChileRekrutierungInsulinresistenz | StoffwechselkrankheitChile
-
Assiut UniversitySouth Egypt Cancer InstituteAbgeschlossenAkute myeloische LeukämieÄgypten
-
University of CopenhagenAbgeschlossenLebensqualität | Krebskachexie | NebenwirkungenDänemark
-
Galderma R&DAbgeschlossen
-
Karadeniz Technical UniversityAbgeschlossenHämodialyse | Einsamkeit | Glück | Anpassung | Tiergestützte Therapie | SymptomTruthahn
-
Istituto Clinico HumanitasAbgeschlossenRetrospektive Studie zur Bewertung molekularer Merkmale zur Vorhersage des Ansprechens auf CetuximabKolorektale NeubildungenItalien
-
Peking UniversityAbgeschlossen
-
University of GlasgowRekrutierungMuskelfunktion | Griffstärke | Omega-3-Fettsäuren | Krillöl | Langfristige BedingungenVereinigtes Königreich
-
Istituto Clinico HumanitasAbgeschlossen